Sandra Killett

New York, New York

Multiple Myeloma

“I was first diagnosed with multiple myeloma in 2010. In 2016 I lost my health insurance when I lost my job. In 2017 I was placed on a life sustaining regimen of medications which included Revlimid. The cost for Revlimid, the treatment for Multiple Myeloma, is about $43,460 every four months. That is an annual cost of $130,380. My co-pay is $2,853. This is an exorbitant amount.

On top of dealing with the stress and fear of having an incurable blood cancer, I had to worry about whether or not I would get help to cover this massive co-pay. I was unable to purchase Revlimid for a month and went without treatment during that time.  This caused me extreme stress and despair, but it also helped me realize why prescription drug pricing is an urgent issue that can mean life or death for some patients.”

Share your story

The prescription drug pricing system in the U.S. is rigged against patients. We are fighting to change that.

Patients For Affordable Drugs will collect patient stories and amplify the voices of patients to make policymakers understand the heavy toll of high priced drugs.

Share your story


Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.